Cancer-associated myositis before and after the COVID-19 pandemic onset: a changing trend
Authors' conclusion
There was a significant increase in the incidence of CAM after the COVID-19 pandemic. IIM diagnosis after the COVID-19 pandemic was an independent predictor of CAM.
Study context
- Population
- Patients with idiopathic inflammatory myopathy (IIM) diagnosed between June 2016 and June 2023
- Participants
- 132 patients
- Exposure
- IIM diagnosed after vs before the COVID-19 pandemic onset
- After COVID-19 pandemic onsetn = 46
- Before COVID-19 pandemicn = 86reference
- Outcome
- Incidence of cancer-associated myositis (CAM)
Main finding
As reported in the abstract
Incidence of CAM (new cases)
After COVID-19 pandemic onset
11
events
Before COVID-19 pandemic
3
events
P < 0.002
Observational data: associations, not effects.
Further findings
Most frequent myositis-specific antibody · significantly higher
P = 0.006
MSA After COVID-19 pandemic onset anti-TIF1γ · Before COVID-19 pandemic anti-Mi2
| Outcome | OR (95% CI) | P value |
|---|---|---|
| Diagnosis after the COVID-19 pandemic as independent predictor of CAM among IIM patientsRegardless of age, sex or previous COVID-19 infection | 0.012 (0.000–0.400) | P = 0.013 |
- Most common IIM: Dermatomyositis (DM) before and after pandemic onset
- P = 0.750
Cancer-associated myositis (CAM) vs non-CAM-IIM patients
- Anti-TIF1γ-positivity more frequent in CAM
- P < 0.001
- Diagnosis after the pandemic more frequent in CAM
- P = 0.001
- No significant differences in vaccination status or previous COVID-19 infection
Original publication
Cancer-associated myositis before and after the COVID-19 pandemic onset: a changing trend. Clin Exp Rheumatol. Published 14 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →